Evaluation of the Clinicopathologic and Genomic Features of CNS Metastases in Soft Tissue Sarcoma

Background: The incidence and risk factors for central nervous system (CNS) metastases in soft tissue sarcoma (STS) are poorly defined. We evaluated the frequency of CNS metastases in STS and associated clinicopathologic and genomic factors. Methods: This retrospective study used the Memorial Sloan Kettering Cancer Center institutional cBioPortal database. Patients with invasive STS, including gastrointestinal stromal tumor, were included. CNS metastases were identified using natural language processing-derived radiology annotations and confirmed by manual chart review. Cumulative incidence was estimated with death as a competing event. Clinicopathologic and genomic associations were evaluated using Firth logistic regression with correction for multiplicity; post-CNS metastasis survival was estimated using Kaplan–Meier analysis. Results: A total of 5379 patients were included. CNS metastases were identified in 161 patients (3.0%), with a 10-year cumulative incidence of 4.5% after accounting for death as a competing event. Median overall survival after CNS metastasis was 4.76 months (95% CI, 3.9–7.5). In one-versus-rest analyses, increased odds of CNS metastasis were observed for alveolar soft part sarcoma (OR 16.61, 95% CI 7.21–35.81; q < 0.001), rhabdomyosarcoma (OR 2.44, 95% CI 1.42–3.97; q = 0.007), non-uterine leiomyosarcoma (OR 2.24, 95% CI 1.45–3.34; q = 0.003), extremity primaries (OR 2.20, 95% CI 1.58–3.05; q < 0.001), head and neck primaries (OR 2.11, 95% CI 1.26–3.35; q = 0.017), and PDGFRB alterations (OR 4.90, 95% CI 2.29–9.41; q = 0.016). KIT alterations were associated with lower odds (OR 0.10, 95% CI 0.02–0.29; q < 0.001). Conclusions: CNS metastases in STS were uncommon but associated with poor survival, with risk varying by histology and primary site.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-16
DOI
https://doi.org/10.3390/cancers18223659
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Evaluation of the Clinicopathologic and Genomic Features of CNS Metastases in Soft Tissue Sarcoma

Carla Saoud, Ping Chi, Adel Shahnam, Lauren Baker Banks et al.
1 links
Cancers
Sarcoma Diagnosis and Treatment
article

Evaluation of the Clinicopathologic and Genomic Features of CNS Metastases in Soft Tissue Sarcoma

Carla Saoud, Ping Chi, Adel Shahnam, Lauren Baker Banks, Aimee Marie Crago, Damon R. Reed, William D. Tap, Mrinal M. Gounder, Mark Andrew Dickson, Sujana Movva, Daniel Jack Reinhorn, Mary Louise Keohan, Robert G. Maki, Olayode O. Babatunde, Sandra P. D’Angelo, Rhoena Desir, Ciara Marie Kelly, Samuel Singer, Kristen DiConza, Justin Jee
article en

Abstract

Background: The incidence and risk factors for central nervous system (CNS) metastases in soft tissue sarcoma (STS) are poorly defined. We evaluated the frequency of CNS metastases in STS and associated clinicopathologic and genomic factors. Methods: This retrospective study used the Memorial Sloan Kettering Cancer Center institutional cBioPortal database. Patients with invasive STS, including gastrointestinal stromal tumor, were included. CNS metastases were identified using natural language processing-derived radiology annotations and confirmed by manual chart review. Cumulative incidence was estimated with death as a competing event. Clinicopathologic and genomic associations were evaluated using Firth logistic regression with correction for multiplicity; post-CNS metastasis survival was estimated using Kaplan–Meier analysis. Results: A total of 5379 patients were included. CNS metastases were identified in 161 patients (3.0%), with a 10-year cumulative incidence of 4.5% after accounting for death as a competing event. Median overall survival after CNS metastasis was 4.76 months (95% CI, 3.9–7.5). In one-versus-rest analyses, increased odds of CNS metastasis were observed for alveolar soft part sarcoma (OR 16.61, 95% CI 7.21–35.81; q < 0.001), rhabdomyosarcoma (OR 2.44, 95% CI 1.42–3.97; q = 0.007), non-uterine leiomyosarcoma (OR 2.24, 95% CI 1.45–3.34; q = 0.003), extremity primaries (OR 2.20, 95% CI 1.58–3.05; q < 0.001), head and neck primaries (OR 2.11, 95% CI 1.26–3.35; q = 0.017), and PDGFRB alterations (OR 4.90, 95% CI 2.29–9.41; q = 0.016). KIT alterations were associated with lower odds (OR 0.10, 95% CI 0.02–0.29; q < 0.001). Conclusions: CNS metastases in STS were uncommon but associated with poor survival, with risk varying by histology and primary site.

CancersVol. 18(22)
Memorial Sloan Kettering Cancer Center (US), Flinders University (AU), Weill Cornell Medicine (US), Weill Cornell Medical Center (US)
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon